Business Context and Reporting Period
Company: cbdMD, Inc. (Ticker: YCBD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended March 31, 2026 (Fiscal Q2 2026)
Business Overview: cbdMD operates nationally recognized CBD brands including cbdMD, Paw CBD, and Bluebird Botanicals, alongside functional mushroom brand ATRx Labs and THC beverage brand Herbal Oasis. The company sources hemp-derived cannabinoids and distributes products via e-commerce and wholesale channels.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2026 |
Six Months Ended March 31, 2026 |
|---|---|---|
| Total Net Sales | $5,640,059 | $10,656,964 |
| Gross Profit | $3,256,922 (57.7% margin) | $6,258,213 (58.7% margin) |
| Operating Loss | $(800,784) | $(1,087,074) |
| Net Loss | $(797,978) | $(1,081,111) |
| Net Loss Attributable to Common Shareholders | $(876,783) | $(1,201,387) |
| Cash and Cash Equivalents | $2,638,243 (as of March 31, 2026) | N/A |
| Working Capital | $5,416,093 | N/A |
| Accumulated Deficit | $(180,636,537) | N/A |
Liquidity: The company reported a net cash increase of $377,001 for the six-month period, driven primarily by $2.0 million in proceeds from the issuance of Series C Preferred Stock. Operating cash flow was negative $1.5 million for the six months ended March 31, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% quarter-over-quarter (Q2 2026 vs. Q2 2025) and 8% year-over-year for the six-month period. This growth was driven by gains in both direct-to-consumer and wholesale channels, partially attributed to the acquisition of Bluebird Botanicals.
- Margin Compression: Gross margin decreased from 62.3% to 57.7% for the quarter. Management attributed this to a shift in sales mix toward wholesale (which grew $0.7 million YoY) and increased warehouse labor costs due to regulatory repacking projects.
- Operating Expenses: Operating expenses increased by $612,526 (17.3%) for the quarter. Significant drivers included $340,000 in labor, marketing, and transaction costs related to the Bluebird acquisition, as well as a $294,938 increase in non-cash stock compensation.
- Acquisition Impact: The Bluebird acquisition, closed in January 2026, created a $75,000 drag on the P&L in Q2 due to integration costs, though management estimates it will contribute over $500,000 in revenue per quarter in future periods.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management remains focused on a path to profitability through portfolio optimization and cost control. They anticipate Bluebird will add incremental revenue in Q3 2026. The company is actively pursuing participation in the President's Medicare reimbursement program (Substance Access Beneficiary Engagement Incentive) launched in April 2026, which allows approved participants to furnish eligible hemp-derived products to Medicare beneficiaries.
Regulatory Risks and Contingencies
- Federal Legislation (H.R. 5371): The "Continuing Appropriations Act of 2026" narrows the federal definition of hemp to a total THC standard and limits consumable products to 0.4 mg of total THC per container. While the majority of current revenue complies, management warns that if implemented as written, this could have a material adverse impact on the business.
- Going Concern: The company has an accumulated deficit of approximately $180.6 million and raised substantial doubt about its ability to continue as a going concern for the next twelve months. Continued operations depend on improving profitability and securing additional funding.
- Preferred Stock Obligations: The company has outstanding Series B and Series C Convertible Preferred Stock accruing dividends at 10% per annum. If equity conditions are not met, these dividends must be paid in cash, creating a quarterly obligation of approximately $70,000.
Unusual Items
The company completed a 1-for-8 reverse stock split in May 2025. Additionally, the company entered into an Equity Line of Credit (ELOC) agreement with C/M Capital Master Fund, LP, allowing for the sale of up to $20 million of common stock, subject to market conditions and registration effectiveness.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to fund operations given the $180.6 million accumulated deficit and negative operating cash flow.
- Regulatory Impact: Monitor the status of H.R. 5371 and potential amendments that could restrict the sale of current THC-containing product lines.
- Preferred Stock Dilution: Assess the potential dilution from the conversion of Series B and Series C Preferred Stock and the impact of accrued dividend payments.
- Bluebird Integration: Track the revenue contribution and synergy realization from the Bluebird Botanicals acquisition against management's $500,000 quarterly estimate.
- ELOC Utilization: Monitor the effectiveness of the Equity Line of Credit as a liquidity source and the associated dilution to common shareholders.